Serum levels of apolipoprotein ApoC1 have been described in a number of systemic tumor
entities as potential biomarkers, but little is known about ApoC1 in neurosurgical patients. A total
of 230 serum samples from 96 patients were analyzed using an ELISA technique. Patient diagnoses
comprised 70 glioblastomas WHO IV◦
, 10 anaplastic astrocytomas III◦
, one anaplastic oligodendroglioma III◦
, one oligodendroglioma II◦
, one diffuse astrocytoma II◦
, one pilocytic astrocytoma I◦
,
and a single case of a spindle cell tumor without WHO grading, as well as 11 spinal interventions.
The mean ApoC1 level of the 230 samples was 132.03 µg/mL (median 86.83, SD 292.91). In the
176 glioblastoma samples, the mean ApoC1 level was 130.0 µg/mL (median 86.23, SD 314.9), which
was neither different from the whole group nor from patients with spinal interventions (215.1 µg/mL,
median 63.6, SD 404.9). In the postoperative samples, the mean ApoC1 level was significantly lower
(85.81 µg/mL) than in the preoperative samples (129.64 µg/mL) and in samples obtained during
adjuvant chemotherapy (168.44 µg/mL). While absolute ApoC1 serum levels in a patient do not
allow for the distinction between neurosurgical histological entities, future analyses will examine
whether the time course of ApoC1 in an individual patient can be related to certain treatment stages.
| Identifer | oai:union.ndltd.org:DRESDEN/oai:qucosa:de:qucosa:87884 |
| Date | 03 November 2023 |
| Creators | Hilbert, Michelle, Kuzman, Peter, Müller, Wolf C., Nestler, Ulf |
| Publisher | MDPI |
| Source Sets | Hochschulschriftenserver (HSSS) der SLUB Dresden |
| Language | English |
| Detected Language | English |
| Type | info:eu-repo/semantics/publishedVersion, doc-type:article, info:eu-repo/semantics/article, doc-type:Text |
| Rights | info:eu-repo/semantics/openAccess |
| Relation | 1021 |
Page generated in 0.0017 seconds